Table 3.
Results of two multivariable generalized ordered logit modelsa with partial proportional odds which examine associations between patient characteristics and the completionb of daily-dose isoniazid treatment for latent tuberculosis infection (N = 1072)
| Model 1: Includes Count of Clinical Risk Factors | Model 2: Includes Specific Clinical Risk Factors | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Independent Variables | Adjusted Odds Ratio | 95% Confidence Interval | p-value | Adjusted Odds Ratio | 95% Confidence Interval | p-value | |||
| Sex | Female | 1.000 | 1.000 | ||||||
| Male | 1.085 | 0.855 | 1.378 | 0.501 | 1.045 | 0.818 | 1.335 | 0.724 | |
| Age Group | 0–14 | 1.000 | 1.000 | ||||||
| 15–29 | 0.547 | 0.351 | 0.854 | 0.008 | 0.552 | 0.353 | 0.863 | 0.009 | |
| 30–44 | 0.597 | 0.385 | 0.925 | 0.021 | 0.599 | 0.386 | 0.930 | 0.022 | |
| 45–64 | 0.584 | 0.370 | 0.920 | 0.020 | 0.574 | 0.362 | 0.909 | 0.018 | |
| Census Region | Northeast | 1.000 | 1.000 | ||||||
| Midwest | 0.934 | 0.588 | 1.483 | 0.772 | 0.933 | 0.587 | 1.484 | 0.771 | |
| South | 0.716 | 0.466 | 1.102 | 0.129 | 0.692 | 0.449 | 1.069 | 0.097 | |
| West | 0.989 | 0.676 | 1.448 | 0.956 | 0.967 | 0.661 | 1.416 | 0.864 | |
| Patient Location | Neither regimen completed vs. ≥6 months completed (completed 6 or 9 month regimen) | ||||||||
| Large central metro county | 1.000 | 1.000 | |||||||
| Large fringe metro county | 0.600 | 0.414 | 0.868 | 0.007 | 0.592 | 0.408 | 0.858 | 0.006 | |
| Any smaller county | 0.767 | 0.495 | 1.189 | 0.235 | 0.776 | 0.500 | 1.203 | 0.256 | |
| < 9 months completed (neither regimen or 6 month regimen completed) vs. ≥9 months completed | |||||||||
| Large central metro county | 1.000 | 1.000 | |||||||
| Large fringe metro county | 0.800 | 0.537 | 1.193 | 0.275 | 0.791 | 0.530 | 1.182 | 0.253 | |
| Any smaller county | 0.767 | 0.495 | 1.189 | 0.235 | 0.776 | 0.500 | 1.203 | 0.256 | |
| % of Households Under FPL in County | < 15% | 1.000 | 1.000 | ||||||
| ≥15% | 0.628 | 0.469 | 0.841 | 0.002 | 0.609 | 0.454 | 0.817 | 0.001 | |
| Insurance Type | Neither regimen completed vs. ≥6 months completed (completed 6 or 9 month regimen) | ||||||||
| HMO | 1.000 | 1.000 | |||||||
| POS | 1.434 | 0.981 | 2.097 | 0.063 | 1.513 | 1.032 | 2.218 | 0.034 | |
| PPO | 1.817 | 1.147 | 2.878 | 0.011 | 1.864 | 1.174 | 2.961 | 0.008 | |
| < 9 months completed (neither regimen or 6 month regimen completed) vs. ≥9 months completed | |||||||||
| HMO | 1.000 | 1.000 | |||||||
| POS | 1.434 | 0.981 | 2.097 | 0.063 | 1.513 | 1.032 | 2.218 | 0.034 | |
| PPO | 2.840 | 1.745 | 4.622 | < 0.001 | 2.921 | 1.789 | 4.767 | < 0.001 | |
| Prescription Size | Neither regimen completed vs. ≥6 months completed (completed 6 or 9 month regimen) | ||||||||
| < 2 month supply | 1.000 | 1.000 | |||||||
| ≥2 month supply | 1.419 | 0.884 | 2.278 | 0.148 | 1.395 | 0.867 | 2.245 | 0.170 | |
| < 9 months completed (neither regimen or 6 month regimen completed) vs. ≥9 months completed | |||||||||
| < 2 month supply | 1.000 | 1.000 | |||||||
| ≥2 month supply | 2.268 | 1.383 | 3.720 | 0.001 | 2.233 | 1.359 | 3.670 | 0.002 | |
| Year INH Regimen Started | 2011 Q3–4 | 1.000 | 1.000 | ||||||
| 2012 Q1–4 | 1.109 | 0.802 | 1.532 | 0.531 | 1.104 | 0.798 | 1.526 | 0.551 | |
| 2013 Q1–4 | 1.268 | 0.906 | 1.774 | 0.167 | 1.261 | 0.901 | 1.766 | 0.177 | |
| 2014 Q1 | 1.333 | 0.720 | 2.468 | 0.361 | 1.333 | 0.718 | 2.473 | 0.363 | |
| State TB Rate | 0.905 | 0.793 | 1.033 | 0.138 | 0.913 | 0.800 | 1.042 | 0.178 | |
| LTBI Diagnostic Test | TST | 1.000 | 1.000 | ||||||
| IGRA | 1.255 | 0.897 | 1.757 | 0.185 | 1.171 | 0.829 | 1.653 | 0.371 | |
| Unknown/Other | 0.813 | 0.616 | 1.071 | 0.141 | 0.812 | 0.615 | 1.071 | 0.141 | |
| Percent Foreign Born in County | 1.004 | 0.989 | 1.019 | 0.612 | 1.004 | 0.989 | 1.019 | 0.636 | |
| Count of Clinical Risk Factors | None | 1.000 | |||||||
| 1 | 1.522 | 1.158 | 2.001 | 0.003 | na | na | na | na | |
| 2 or more | 1.816 | 1.188 | 2.778 | 0.006 | na | na | na | na | |
| Diagnosis of Contact w/ TB | No diagnosis | na | na | na | na | 1.000 | |||
| Had diagnosis | na | na | na | na | 1.289 | 0.916 | 1.814 | 0.145 | |
| History of TB/Late Effects | No diagnosis | na | na | na | na | 1.000 | |||
| Had diagnosis | na | na | na | na | 1.152 | 0.655 | 2.027 | 0.624 | |
| HIV Positive | No diagnosis | na | na | na | na | 1.000 | |||
| Had diagnosis | na | na | na | na | 2.578 | 1.377 | 4.827 | 0.003 | |
| Diabetes | No diagnosis or medication | na | na | na | na | 1.000 | |||
| Had diagnosis or medication | na | na | na | na | 1.458 | 0.902 | 2.355 | 0.124 | |
| Tobacco | No diagnosis or medication | na | na | na | na | 1.000 | |||
| Had diagnosis or medication | na | na | na | na | 1.254 | 0.766 | 2.052 | 0.368 | |
| Immuno-suppressive Medications | No medication | na | na | na | na | 1.000 | |||
| Had medication | na | na | na | na | 1.470 | 0.997 | 2.167 | 0.052 | |
aConstraints for parallel lines were applied to all independent variables except patient location, insurance type, and isoniazid days supply received
bFor both models, isoniazid treatment completion was categorized as 1) less than 6 months completed, 2) at least 6 months but less than 9 months completed, and 3) 9 or more months completed
Abbreviations: INH isoniazid, FPL federal poverty level, TB tuberculosis, TST tuberculin skin test, IGRA interferon-gamma release assays, LTBI latent tuberculosis infection, HMO health maintenance organization, POS point of service, PPO preferred provider organization